Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a title he’s held since 2017. He succeeds CFO Hunter Smith, who was serving as president and CEO on an interim basis. Meeker was president and CEO of KSQ Therapeutics Inc., and

Read the full 491 word article

How to gain access

Continue reading with a
two-week free trial.